Clinical Practice Recommendations for the Management and Prevention of Cisplatin-Induced Hearing Loss Using Pharmacogenetic Markers

Authors

Jong W. Lee, The University of British Columbia
Kusala Pussegoda, BC Children's Hospital Research Institute
Shahrad R. Rassekh, BC​ Children​'​​s Hospital
Jose G. Monzon, University of Calgary
Geoffrey Liu, University of Toronto
Soomi Hwang, The University of British Columbia
Amit P. Bhavsar, BC Children's Hospital Research Institute
Sheila Pritchard, BC Children's Hospital Research Institute
Colin J. Ross, BC Children's Hospital Research Institute
Ursula Amstutz, BC​ Children​'​​s Hospital
Bruce C. Carleton, BC​ Children​'​​s Hospital
Michael R. Hayden
Stuart MacLeod
Anne Smith
Liam Brunham
Folefac Aminkeng
Neil H. Shear
Gideon Koren
Shinya Ito
Parvaz Madadi
Michael J. RiederFollow
Richard Kim
Maurica Maher
David Flockhart

Document Type

Article

Publication Date

8-1-2016

Journal

Therapeutic Drug Monitoring

Volume

38

Issue

4

First Page

423

Last Page

431

URL with Digital Object Identifier

10.1097/FTD.0000000000000298

Abstract

Currently no pharmacogenomics-based criteria exist to guide clinicians in identifying individuals who are at risk of hearing loss from cisplatin-based chemotherapy. This review summarizes findings from pharmacogenomic studies that report genetic polymorphisms associated with cisplatin-induced hearing loss and aims to (1) provide up-to-date information on new developments in the field, (2) provide recommendations for the use of pharmacogenetic testing in the prevention, assessment, and management of cisplatin-induced hearing loss in children and adults, and (3) identify knowledge gaps to direct and prioritize future research. These practice recommendations for pharmacogenetic testing in the context of cisplatin-induced hearing loss reflect a review and evaluation of recent literature, and are designed to assist clinicians in providing optimal clinical care for patients receiving cisplatin-based chemotherapy.